A phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with renal cell carcinoma

被引：0

作者：

Lee, C-H. ^{[1
]}

Makker, V. ^{[1
]}

Rasco, D. ^{[2
]}

Taylor, M. ^{[3
]}

Dutcus, C. ^{[4
]}

Shumaker, R. ^{[4
]}

Schmidt, E. V. ^{[5
]}

Stepan, D. ^{[4
]}

Li, D. ^{[4
]}

Motzer, R. J. ^{[1
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Genitourinary Oncol, 1275 York Ave, New York, NY 10021 USA

[2] START, Med Oncol, San Antonio, TX USA

[3] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA

[4] Eisai Inc, Woodcliff Lake, NJ USA

[5] Merck & Co Inc, Kenilworth, NJ USA

来源：

ANNALS OF ONCOLOGY | 2017年 / 28卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

847O

引用

页数：2

共 50 条

[11] A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): Updated results
Llovet, Josep
Finn, Richard
Ikeda, Masfumi
Sung, Max
Baron, Ari
Kudo, Masatoshi
Okusaka, Takuji
Kobayashi, Masahiro
Kumada, Hiromitsu
Kaneko, Suichi
Pracht, Marc
Mamontov, Konstantin
Meyer, Tim
Mody, Kalgi
Kubota, Tomoki
Dutcus, Corina
Saito, Kenichi
Siegel, Abby
Dubrovsky, Leonid
Young, Louise
Zhu, Andrew X.
[J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 189 - 190
[12] Lenvatinib plus pembrolizumab in patients with renal cell carcinoma: Updated results
Lee, Chung-Han
Makker, Vicky
Rasco, Drew
Taylor, Mathew
Stepan, Daniel E.
Shumaker, Robert
Schmidt, Emmett V.
Guo, Matthew
Dutcus, Corina
Young, Louise
Motzer, Robert
[J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 174 - 175
[13] A Phase 1b Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma: Extended Analysis of Study 116
Kudo, Masatoshi
Finn, Richard S.
Ikeda, Masafumi
Sung, Max W.
Baron, Ari D.
Okusaka, Takuji
Kobayashi, Masahiro
Kumada, Hiromitsu
Kaneko, Shuichi
Pracht, Marc
Meyer, Tim
Nagao, Satoshi
Saito, Kenichi
Mody, Kalgi
Ramji, Zahra
Dubrovsky, Leonid
Llovet, Josep M.
[J]. LIVER CANCER, 2024, 13 (04)
[14] Exploratory circulating biomarker analyses: lenvatinib plus pembrolizumab (L plus P) in a phase 1b trial in unresectable hepatocellular carcinoma (uHCC).
Zhu, Andrew X.
Llovet, Josep M.
Kobayashi, Masahiro
Ikeda, Masafumi
Pracht, Marc
Sung, Max W.
Baron, Ari David
Kudo, Masatoshi
Meyer, Tim
Okusaka, Takuji
Kumada, Hiromitsu
Kaneko, Shuichi
Hoshi, Taisuke
Saito, Kenichi
Li, Shuyu D.
Funahashi, Yasuhiro
Minoshima, Yukinori
Dubrovsky, Leonid
Finn, Richard S.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[15] A Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Endometrial Carcinoma
Makker, Vicky
Rasco, Drew
Dutcus, Corina
Stepan, Daniel
Li, Di
Schmidt, Emmett
Shumaker, Robert
Young, Louise
Taylor, Matthew
[J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 152 - 153
[16] PHASE 3 STUDY OF PEMBROLIZUMAB plus BELZUTIFAN plus LENVATINIB OR PEMBROLIZUMAB/QUAVONLIMAB plus LENVATINIB VERSUS PEMBROLIZUMAB plus LENVATINIB AS FIRST-LINE TREATMENT FOR ADVANCED RENAL CELL CARCINOMA
Choueiri, Toni
Plimack, Elizabeth
Powles, Thomas
Voss, Martin
Gurney, Howard
Silverman, Rachel
Perini, Rodolfo
Rodriguez-Lopez, Karla
Rini, Brian
[J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A447 - A447
[17] Lenvatinib plus pembrolizumab in patients with renal cell carcinoma: Updated results.
Lee, Chung-Han
Makker, Vicky
Rasco, Drew W.
Taylor, Matthew H.
Stepan, Daniel E.
Shumaker, Robert Charles
Schmidt, Emmett V.
Guo, Matthew
Dutcus, Corina E.
Motzer, Robert J.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[18] Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Motzer, Robert
Alekseev, Boris
Rha, Sun-Young
Porta, Camillo
Eto, Masatoshi
Powles, Thomas
Gruenwald, Viktor
Hutson, Thomas E.
Kopyltsov, Evgeny
Mendez-Vidal, Maria J.
Kozlov, Vadim
Alyasova, Anna
Hong, Sung-Hoo
Kapoor, Anil
Alonso Gordoa, Teresa
Merchan, Jaime R.
Winquist, Eric
Maroto, Pablo
Goh, Jeffrey C.
Kim, Miso
Gurney, Howard
Patel, Vijay
Peer, Avivit
Procopio, Giuseppe
Takagi, Toshio
Melichar, Bohuslav
Rolland, Frederic
De Giorgi, Ugo
Wong, Shirley
Bedke, Jens
Schmidinger, Manuela
Dutcus, Corina E.
Smith, Alan D.
Dutta, Lea
Mody, Kalgi
Perini, Rodolfo F.
Xing, Dongyuan
Choueiri, Toni K.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (14): : 1289 - 1300
[19] Phase 3 study of first-line treatment with pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib for advanced renal cell carcinoma (RCC).
Choueiri, Toni K.
Plimack, Elizabeth R.
Powles, Thomas
Voss, Martin H.
Gurney, Howard
Silverman, Rachel Kloss
Perini, Rodolfo F.
Rodriguez-Lopez, Karla
Rini, Brian I.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
[20] Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study
Lee, Chung-Han
Shah, Amishi Yogesh
Rasco, Drew
Rao, Arpit
Taylor, H. Matthew
Di Simone, Christopher
Hsieh, J. James
Pinto, Alvaro
Shaffer, R. David
Sarrio, Regina Girones
Cohn, Allen Lee
Vogelzang, J. Nicholas
Bilen, Mehmet Asim
Ribe, Sara Gunnestad
Goksel, Musaberk
Tennoe, Oyvind Krohn
Richards, Donald
Sweis, F. Randy
Courtright, Jay
Heinrich, Daniel
Jain, Sharad
Wu, Jane
Schmidt, V. Emmett
Perini, F. Rodolfo
Kubiak, Peter
Okpara, E. Chinyere
Smith, D. Alan
Motzer, J. Robert
[J]. LANCET ONCOLOGY, 2021, 22 (07): : 946 - 958

← 1 2 3 4 5 →